Tang Capital reports 2.80% Tarsus Pharmaceuticals (TARS) stake in 13G/A
Rhea-AI Filing Summary
Tarsus Pharmaceuticals, Inc. received an amended Schedule 13G/A showing that investment entities associated with Kevin Tang collectively beneficially own 1,188,624 shares of Tarsus common stock. This represents 2.80% of the company’s outstanding common shares as of October 29, 2025.
The shares are held with shared voting and dispositive power through Tang Capital Management, LLC and its affiliated funds, including Tang Capital Partners, Tang Capital Partners International, Tang Capital Partners III, Inc., and Tang Capital Partners IV, Inc. The filing notes that the securities are not held for the purpose of changing or influencing control of Tarsus.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What ownership stake in Tarsus Pharmaceuticals (TARS) is reported in this Schedule 13G/A?
The filing reports that Tang Capital–affiliated entities beneficially own 1,188,624 shares of Tarsus Pharmaceuticals common stock, representing 2.80% of the outstanding shares as of October 29, 2025. This reflects an ownership level below the 5% reporting threshold.
Who are the reporting persons in the Tarsus Pharmaceuticals (TARS) Schedule 13G/A?
The reporting persons are Tang Capital Management, LLC, Kevin Tang, Tang Capital Partners, Tang Capital Partners International, Tang Capital Partners III, Inc., and Tang Capital Partners IV, Inc. They report shared voting and dispositive power over the same 1,188,624 Tarsus common shares.
What does the certification in the Tarsus (TARS) Schedule 13G/A say about control intentions?
The certification states the securities were not acquired and are not held for the purpose of changing or influencing control of Tarsus. It also notes they are not held in connection with any transaction having that control-related purpose, other than activities tied to a specific nomination rule.